Medication topics
Infliximab articles covering Remicade, Inflectra, Renflexis, Avsola, Zymfentra, anti-TNF therapy, safety, and access. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
Page 1 of 3 · 143 articles
If you have Crohn’s disease with perianal fistulas and are treated with infliximab, this study suggests the drug is cleared faster and trough levels are often lower after standard dosing — which may mean you need higher...
This analysis suggests delivery method for the same anti‑TNF (infliximab) may affect long‑term clinical and endoscopic outcomes in ileal-predominant Crohn’s disease. If confirmed, route of maintenance dosing could...
This study addresses a common problem in Crohn's patients on infliximab: low drug levels despite IV dosing. It suggests switching to a subcutaneous infliximab formulation can raise and stabilize trough concentrations...
People with IBD and coexisting primary sclerosing cholangitis (PSC) are at higher colorectal neoplasia risk and may respond differently to IBD medicines. This meta-analysis compiles available evidence on commonly used...
Staying on an immunomodulator with anti-TNF therapy was linked to greater long-term persistence of the biologic drug, which matters because loss of response to anti-TNF agents is a common problem in Crohn’s disease....
The study focuses on children newly diagnosed with Crohn's disease who start anti-TNF treatment and aims to identify biological and clinical markers tied to complete intestinal healing after one year; results could help...
Patients on or considering infliximab may be interested because the paper identifies a possible molecular reason some people don’t respond and tests strategies that could, in principle, improve response to infliximab.
Perianal fistulas are a common, challenging Crohn's complication that often need combined medical and surgical care; understanding local practice patterns helps patients and clinicians anticipate typical treatments and...
A blood biomarker that predicts anti-TNF response could help people with IBD and their clinicians choose the right biologic sooner, avoiding ineffective treatment. This study reports that lower baseline serum oncostatin...
Some infections (here, HIV) can closely mimic very early onset IBD. Recognizing progressive lymphopenia or unusual infections can change diagnosis and treatment, which matters because immunosuppression can worsen...
For people hospitalized with acute severe UC, the findings suggest that measuring early infliximab pharmacokinetics could help personalize rescue therapy and potentially reduce colectomy risk by identifying who may need...
Based on the title and source metadata, this appears to be an opinion or commentary related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Translational gastroenterology...
Predicting early need for infliximab could help identify children with Crohn’s disease who may benefit from earlier biologic therapy instead of prolonged conventional treatment. A reliable prediction tool may shorten...
Many people with Crohn’s disease or ulcerative colitis use biologic drugs; new clinical and real-world data about a subcutaneous infliximab option could affect treatment choice, switching decisions, and practical use in...
This analysis suggests a subcutaneous formulation of infliximab may lead to better clinical and endoscopic outcomes than intravenous infliximab for ileal-involved Crohn’s disease, which could affect treatment choices and...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Inflammatory Bowel Diseases.
Patients on biologic therapy often have drug levels and antidrug antibodies measured to guide care. This study suggests prior biologic history, disease type (UC vs CD) and which biologic is currently used may affect...
The study explores whether blood redox biomarkers relate to short- and long-term response to infliximab or vedolizumab, which could help predict who benefits from these biologics. It also suggests a link between...
The study suggests that using infliximab as first-line therapy (rather than IV corticosteroids) may produce more durable remission and reduce long-term colectomy risk in moderate-to-severe ulcerative colitis.
Conference analyses describe how subcutaneous infliximab performs after stopping IV treatment and when compared with IV infliximab for ileal/ileocolonic Crohn's — information that could affect treatment decisions for...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Infliximab, and Anti-TNF. The original article is from Frontiers in pediatrics.
Modeled cost savings and fewer hospital visits could affect access to infliximab for people with Crohn’s disease and other autoimmune conditions in Jordan, potentially increasing the number of patients who can be treated...
Adherence affects how well advanced IBD treatments work. Knowing which drug forms and patient factors link to missed doses can help patients and clinicians plan support strategies.
This review directly addresses whether switching from originator infliximab to a biosimilar affects disease control or safety in children with IBD — a common practical concern for families and clinicians. Its pooled data...
The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...
A rapidly growing abdominal mass or unexplained systemic decline in someone with Crohn's disease may represent a rare malignancy (plasmablastic neoplasm) rather than infection or a disease flare; prompt biopsy is...
Families and clinicians deciding on a first biologic for a child with ulcerative colitis need to know which drugs have pediatric-specific evidence. This review shows infliximab has the strongest pediatric data, while...
If local norepinephrine promotes neutrophil‑driven inflammation in UC, that could help explain disease progression in some patients and point to biomarkers (ADRB2‑rich neutrophils) that might predict response to anti‑TNF...
Perianal fistulas cause significant morbidity and often need both medical and surgical treatments. Newer drug options and updated guideline support earlier use of advanced therapies, which may improve healing and reduce...
Perianal fistulizing Crohn's often causes significant symptoms and requires both medical and surgical approaches. Newer biologics and JAK inhibitors expand treatment options and guidelines increasingly support earlier...
A subcutaneous option for infliximab could simplify maintenance therapy, reduce infusion visits, and change how drug levels and accompanying immunomodulators are managed — issues many people with IBD and their clinicians...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Inflammatory Bowel Diseases.
For people with UC who do not respond to tacrolimus, adding infliximab may induce remission and reduce the short-term need for colectomy. The findings point to a potential rescue strategy and an option to transition to...
People with IBD on biologic therapies may benefit from accurate drug-level testing to guide treatment decisions.
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Infliximab, and Anti-TNF. The original article is from Polish archives of internal medicine.
Bright, round objects on stomach CT scans can be mistaken for retained pills or bleeding. For people with Crohn's disease who commonly receive CT enterography and may have bile reflux or duodenal narrowing, this report...
A single‑patient report suggests guselkumab (IL‑23 inhibitor) may control both refractory pyoderma gangrenosum and coexisting Crohn disease when several prior treatments failed.
This registry will gather real-world safety and effectiveness data on infliximab in Chinese children with moderate-to-severe Crohn's disease, which can help clinicians and families understand how the drug performs...
This large real-world study found upadacitinib was associated with lower risk of treatment failure and more corticosteroid-free stability compared with several other advanced therapies for ulcerative colitis —...
Children with IBD and their caregivers may be interested in subcutaneous infliximab as an alternative to regular IV infusions because this review suggests it can maintain drug levels and remission after switching, with...
Hospitalized patients with acute severe ulcerative colitis often need rescue therapy to avoid colectomy.
The trial suggests starting infliximab early can delay the need for further biologic escalation in children with moderate-to-severe Crohn’s disease, and that stopping anti‑TNF after induction often leads to relapse.
Cure8 could only read part of this source from American Journal of Therapeutics, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Infliximab, and Ustekinumab.
A PopPK model for subcutaneous infliximab could enable more personalized dosing when starting or switching patients to home-administered infliximab, potentially improving drug exposure and management for people with IBD.
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...
This study compares first‑line vedolizumab versus TNF antagonist strategies in biologic‑naive ulcerative colitis patients over multiple years — information that could affect treatment choice and expectations about...
The study suggests active smoking reduces the effectiveness of anti-TNF biologics in people with IBD, which could affect treatment response and the need to switch or escalate therapies. This supports including smoking...
Patients and clinicians often face trade-offs when managing overlapping immune-mediated diseases. This report shows how past thromboembolic events and disease remission status can steer therapy away from JAK inhibitors...
